Latest News of PCRX
The three-year loss for Pacira BioSciences (NASDAQ:PCRX) shareholders likely driven by its shrinking earnings
By Yahoo! Finance |
1 month ago
Despite Pacira BioSciences' disappointing returns over three years, a recent 14% share price increase offers hope. Profitability and revenue growth suggest potential for further gains. Insiders buying...
Pacira BioSciences, Inc. (PCRX) Stock Price, News, Quote & History - Yahoo Finance
By Yahoo! Finance |
2 months ago
Pacira BioSciences, Inc. announced that its U.S. Patent No. 11,033,495 was deemed invalid by the U.S. District Court for the District of New Jersey....
Pacira BioSciences, Inc. (PCRX) Stock Price, News, Quote & History
By Yahoo! Finance |
4 months ago
Pacira BioSciences will join a fireside chat at the 2024 Jefferies Global Healthcare Conference on June 6. The event will be live-streamed on the company's website, with a replay available for two wee...
-
Declining Stock and Decent Financials: Is The Market Wrong About Pacira BioSciences, Inc. (NASDAQ:PCRX)?
By Yahoo! Finance | 5 months agoDespite a 7.9% stock decline, Pacira BioSciences' financials remain strong with a 7.9% Return on Equity (ROE). While lower than industry average, its reinvestment strategy has led to positive earnings...
-
Insider Sale: Chief Medical Officer Jonathan Slonin Sells Shares of Pacira BioSciences Inc (PCRX)
By Yahoo! Finance | 5 months agoChief Medical Officer of Pacira BioSciences, Jonathan Slonin, sold 5,012 shares of the company, now owning 98,869.475 shares. The company focuses on non-opioid products for post-surgical pain manageme...